ONO4059-Analog

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:ONO4059-Analog, CAS#1351635-67-0, is a potent and selective BTK inhibitor, and is astructural analogue of ONO-4059. ONO4059 is currently under clinical trials. Note: ONO4059 HCl has CAS#1439901-97-9; ONO4059 free base has CAS#1351636-18-4.

Price and Availability

ONO4059-Analog, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 205914Name: ONO4059-AnalogCAS#: 1351635-67-0 (ONO-4059-analog)Chemical Formula: C25H24N6O3Exact Mass: 456.19099Molecular Weight: 456.51Elemental Analysis: C, 65.78; H, 5.30; N, 18.41; O, 10.51

Related CAS #:1439901-97-9 (HCl)1351636-18-4 (free base)1351635-67-0 (ONO-4059-analog)

Synonym:ONO4059-Analog; ONO 4059-Analog; ONO-4059-Analog; GS 4059-Analog; GS-4059-Analog; GS4059-Analog.

IUPAC/Chemical Name:(S)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one

InChi Key:KSUDUUBCXJUFRL-SFHVURJKSA-N

InChi Code:InChI=1S/C25H24N6O3/c1-2-21(32)29-14-6-7-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-10-12-20(13-11-17)34-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m0/s1

SMILES Code:O=C1N(C2=CC=C(C=C2)OC3=CC=CC=C3)C4=C(N)N=CN=C4N1[C@@H]5CN(C(C=C)=O)CCC5

Technical Data

Additional Information

Note: As of 5/19/2016,Sci-Finder listed ONO4059 hasCAS#1351635-67-0.

In a recent paper ( Blood. 2016 Jan 28;127(4):411-9.), ONO-4059has 1351636-18-4

We consider the structure in paper (( Blood. 2016 Jan 28;127(4):411-9.) is more reliable. Thus we rename CAS#1351635-67-0 as ONO4059-analog

References

1: Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.PubMed PMID: 26957112; PubMed Central PMCID: PMC4784459.

2: Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. PubMed PMID: 26542378; PubMed Central PMCID: PMC4731845.

3: Robak P, Smolewski P, Robak T. Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opin Emerg Drugs. 2015 Sep;20(3):423-47. doi: 10.1517/14728214.2015.1046432. Epub 2015 Jul 11. Review. PubMed PMID: 26153226.

4: Burger JA. Bruton"s tyrosine kinase (BTK) inhibitors in clinical trials. CurrHematol Malig Rep. 2014 Mar;9(1):44-9. doi: 10.1007/s11899-013-0188-8. Review. PubMed PMID: 24357428.

4: Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. Review. PubMed PMID: 23958373; PubMed Central PMCID: PMC3751776.